GLPwatch
Rybelsus vs Xultophy
Drug comparison
Last updated 2026-05-28 15:46 UTCRybelsus is an oral medication containing semaglutide, made by Novo Nordisk, and is FDA-approved to treat type 2 diabetes. Xultophy is a once-daily injection containing liraglutide, also made by Novo Nordisk, and is FDA-approved for the same use. The main difference is how they're taken—Rybelsus is a pill, while Xultophy is an injection.
AI summary of the sources below.
| Rybelsus | Xultophy | |
|---|---|---|
| Active ingredient | semaglutide | liraglutide |
| Manufacturer | novo-nordisk | novo-nordisk |
| Route | oral | subcutaneous injection |
| FDA-approved for | type 2 diabetes | type 2 diabetes |
| Label updated | 2026-01-30 | 2025-10-14 |